Tissue acquired with endoscopic ultrasound–guided fine-needle biopsy was used to grow organoids successfully in two thirds of pancreatic tumors sampled.
Specific signatures may be able to identify which patients are most likely to respond to platinum-based chemotherapy.
Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.
Patients who received metastasis-directed therapy had somewhat longer androgen-deprivation therapy–free survival.
Treatment with anakinra conferred a complete response in 95% of patients.
Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.
Highlights of the latest research
A perspective on the most important research in the field from the past year
Major molecular response rate was significantly higher with bosutinib, but with increased gastrointestinal toxicity.
Large meta-analysis reinforces that, regardless of initial tumor size or nodal burden category, cumulative risk for distant recurrence escalates with increasing follow-up time.
Prof. Dr. med. Christoph Rochlitz
Chefarzt Onkologie Universitätsspital Basel
E-Mail: E-Mail anzeigen
Daten nach 8 Jahren Follow-up in der WHI(Women’s Health Initiative)-Studie hatten eine gewisse Reduktion der Brustkrebstodesfälle durch eine Diät gezeigt, bei der weniger Fett, aber mehr Früchte, Gemüse und Ballaststoffe verzehrt wurden. Im jetzigen Bericht nach 16 Jahren Follow-up war diese Reduktion statistisch nicht mehr signifikant, es wurden aber eine leichte Verminderung der Zahl der prognostisch ungünstigeren Tumoren und weniger kardiovaskuläre Todesfälle berichtet.
First-line therapy demonstrated antitumor activity in a phase II study.
Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.
The use of rituximab following consolidation therapy and autologous stem cell transplantation significantly improved patient outcomes.
Short-term reductions in agitation were helpful, but other components of delirium need further study.
Adding durvalumab to standard therapy significantly improved outcomes, but longer follow-up is required.
Long-term results confirm that survival is noninferior with sentinel versus axillary dissection.
More intense preoperative chemotherapy fails to improve survival.
The anti-PD-1 agent nivolumab was active in biomarker-defined patients with microsatellite instability-high or DNA mismatch repair-deficient disease.
Women's Health Initiative randomized trial findings suggest lowering dietary fat also lowers mortality after breast cancer.
Treatment was effective for 70% of hemorrhages associated with apixaban or rivaroxaban.